Boosting cancer immunotherapy with anti-CD137 antibody therapy

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3113-3120

  Yonezawa, Atsushi ^a,b   Dutt, Suparna ^c   Chester, Cariad ^a   Kim, Jeewon ^d   Kohrt, Holbrook E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c STANFORD UNIVERSITY   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CD137 MONOCLONAL ANTIBODY; CD20 ANTIBODY; CETUXIMAB; DINUTUXIMAB; ELOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2 MONOCLONAL ANTIBODY; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IPILIMUMAB; MB 20 11; MONOCLONAL ANTIBODY; NIVOLUMAB; OFATUMUMAB; PANITUMUMAB; PEMBROLIZUMAB; PERTUZUMAB; PF 05082566; RAMUCIRUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB; VASCULOTROPIN ANTIBODY; CD137 ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DENDRITIC CELL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FATIGUE; GLIOBLASTOMA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MERKEL CELL TUMOR; MULTIPLE MYELOMA; NATURAL KILLER CELL; NEUROBLASTOMA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; STOMACH CANCER; TREATMENT WITHDRAWAL; UTERINE CERVIX CANCER; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84942853584     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0263     Document Type: Review

References (70)

1. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science 2013; 341: 1192-8.
2. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74.
3. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
4. Brufsky AM Current approaches and emerging directions in HER2-resistant breast cancer. Breast Cancer 2014; 8: 109-18.
5. VanEmburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol 2014; 8: 1084-94.
6. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-90.
7. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and coinhibition. Nat Rev Immunol 2013; 13: 227-42.
8. Yao S, Zhu Y, Chen L. Advancesintargeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013; 12: 130-46.
9. Li SY, Liu Y. Immunotherapy ofmelanoma with the immunecostimulatory monoclonal antibodies targeting CD137. Clin Pharmacol 2013; 5: 47-53.
10. McNutt M. Cancer immunotherapy. Science 2013; 342: 1417.
11. Areas to watch in 2015. Science 2014; 346: 1450.
12. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumabinpatientswith metastatic melanoma. N Engl J Med 2010; 363: 711-23.
13. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
14. Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134-40.
15. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL. Multilayered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 2008; 29: 383-90.
16. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012; 11: 1062-70.
17. Houot R, Kohrt H, Levy R. Boosting antibody-dependent cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012; 1: 957-8.
18. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A 1989; 86: 1963-7.
19. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47-55.
20. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682-5.
21. Ju SA, Lee SC, Kwon TH, Heo SK, Park SM, Paek HN, et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 2005; 83: 344-51.
22. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10: 1088-94.
23. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002; 109: 651-9.
24. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34: 236-50.
25. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9: 271-85.
26. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013; 123: 2447-63.
27. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6: e19499.
28. Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med 2013; 11: 215.
29. Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, et al. Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res 2012; 72: 1239-47.
30. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009; 114: 3431-8.
31. Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8T cells in a CD40-dependent-dependent manner. J Immunol 2002; 169: 1792-800.
32. Murillo O, Dubrot J, Palazon A, Arina A, Azpilikueta A, Alfaro C, et al. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009; 39: 2424-36.
33. Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, Teitz-Tennenbaum S, et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004; 64: 8411-9.
34. Wu C, Guo H, Wang Y, Gao Y, Zhu Z, Du Z. Extracellular domain of human 4-1BBL enhanced the function of cytotoxic T-lymphocyte induced by dendritic cell. Cell Immunol 2011; 271: 118-23.
35. Pilones KA, Aryankalayil J, Babb JS, Demaria S. Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes. J Immunother Cancer 2014; 2: 37.
36. Luetke-Eversloh M, Killig M, Romagnani C. Signatures of human NK cell development and terminal differentiation. Front Immunol 2013; 4: 499.
37. Caligiuri MA Human natural killer cells. Blood 2008; 112: 461-9.
38. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cellsexpress 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190: 167-72.
39. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117: 2423-32.
40. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122: 1066-75.
41. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014; 124: 2668-82.
42. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001; 61: 2031-7.
43. Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006; 66: 7276-84.
44. Westwood JA, Matthews GM, Shortt J, Faulkner D, Pegram HJ, Duong CP, et al. Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. Leuk Res 2014; 38: 948-54.
45. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006; 12: 693-8.
46. Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, et al. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 2010; 184: 5493-501.
47. Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ. CD1d-based combination therapy eradicates established tumors in mice. J Immunol 2009; 183: 1911-20.
48. Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z, et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 2004; 173: 3002-12.
49. Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013; 8: e84927.
50. Chen S, Lee LF, Fisher TS, Jessen B, Elliott M, Evering W, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res 2015; 3: 149-60.
51. Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, Kondo T, et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res 2015; 35: 129-36.
52. Lee H, Park HJ, Sohn HJ, Kim JM, Kim SJ. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal. J Surg Res 2011; 169: e43-50.
53. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P, et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces Tcell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 2005; 116: 934-43.
54. Westwood JA, Potdevin Hunnam TC, Pegram HJ, Hicks RJ, Darcy PK, Kershaw MH. Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. PLoS One 2014; 9: e95847.
55. Sin JI, Kim H, Ahn E, Jeon YH, Park WS, Lee SY, et al. Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett 2013; 330: 190-9.
56. John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res 2012; 72: 1651-60.
57. Jensen BA, Pedersen SR, Christensen JP, Thomsen AR. The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS One 2013; 8: e66081.
58. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012; 4: 511-27.
59. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011; 108: 7142-7.
60. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15: 69-77.
61. Chester C, Marabelle A, Houot R, Kohrt HE. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. Curr Opin Immunol 2015; 33C: 1-8.
62. Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 2008; 26 (15 suppl 3007).
63. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007; 178: 4194-213.
64. Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BS. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol 2004; 173: 4218-29.
65. Kohrt HE, Godwin JE, Lossos IS, Williams ME, Timmerman J, Link BK, et al. A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies. J Clin Oncol 31, 2013 (suppl; abstr TPS3108).
66. Chester C, Chang S, Kurland JF, Sagiv-Barfi I, Czerwinski D, Rajapaksa A, et al. Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma. J Clin Oncol 32: 5s, 2014 (suppl; abstr 3017).
67. Melero I, Gangadhar TC, Kohrt HE, Segal NH, Logan T, Urba WJ, et al. A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). J Clin Oncol 31, 2013 (suppl; abstr TPS3107).
68. Segal NH, Gopal AK, Bhatia S, Kohrt HE, Levy R, Pishvaian MJ, et al. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. J Clin Oncol 32: 5s, 2014 (suppl; abstr 3007).
69. Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, et al. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy. J Immunother 2012; 35: 460-72.
70. +T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 2004; 109: 499-506.